Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Luciano Quaranta,1,* Ivano Riva,1,* Andreas Katsanos,2 Irene Floriani,3 Marco Centofanti,4,&dagger; Anastasios G P Konstas51Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy; 2Ophthalmology Department, University of Ioannina, Ioannina, Greece; 3Laboratory of Clinical Resea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Quaranta L, Riva I, Katsanos A, Floriani I, Centofanti M, Konstas AG
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/46733ebdfbc847ca9f233c8e141f473b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:46733ebdfbc847ca9f233c8e141f473b
record_format	dspace
spelling	oai:doaj.org-article:46733ebdfbc847ca9f233c8e141f473b2021-12-02T00:09:29ZSafety and efficacy of travoprost solution for the treatment of elevated intraocular pressure1177-5483https://doaj.org/article/46733ebdfbc847ca9f233c8e141f473b2015-04-01T00:00:00Zhttp://www.dovepress.com/safety-and-efficacy-of-travoprost-solution-for-the-treatment-of-elevat-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Luciano Quaranta,1,* Ivano Riva,1,* Andreas Katsanos,2 Irene Floriani,3 Marco Centofanti,4,&dagger; Anastasios G P Konstas51Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy; 2Ophthalmology Department, University of Ioannina, Ioannina, Greece; 3Laboratory of Clinical Research, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 4DSCMT, University of Tor Vergata, Rome, Italy; 5Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece*These authors contributed equally to this work; &dagger;Dr Centofanti passed away on 1 March 2015Abstract: Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.Keywords: prostaglandin analogue, glaucoma, ocular hypertensionQuaranta LRiva IKatsanos AFloriani ICentofanti MKonstas AGDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 633-643 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Quaranta L Riva I Katsanos A Floriani I Centofanti M Konstas AG Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
description	Luciano Quaranta,1,* Ivano Riva,1,* Andreas Katsanos,2 Irene Floriani,3 Marco Centofanti,4,&dagger; Anastasios G P Konstas51Centre for the Study of Glaucoma, University of Brescia, Brescia, Italy; 2Ophthalmology Department, University of Ioannina, Ioannina, Greece; 3Laboratory of Clinical Research, IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 4DSCMT, University of Tor Vergata, Rome, Italy; 5Glaucoma Unit, 1st University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece*These authors contributed equally to this work; &dagger;Dr Centofanti passed away on 1 March 2015Abstract: Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure (IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular meshwork. Several studies have shown that topical administration of travoprost induces a mean IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When compared with timolol, travoprost is more effective at reducing IOP, while generally no difference has been found in the head-to-head comparison with other prostaglandin analogues. The fixed combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to the concomitant administration of the two drugs. Recently, a new preservative-free formulation of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for patients affected with elevated IOP.Keywords: prostaglandin analogue, glaucoma, ocular hypertension
format	article
author	Quaranta L Riva I Katsanos A Floriani I Centofanti M Konstas AG
author_facet	Quaranta L Riva I Katsanos A Floriani I Centofanti M Konstas AG
author_sort	Quaranta L
title	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
title_short	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
title_full	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
title_fullStr	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
title_full_unstemmed	Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
title_sort	safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/46733ebdfbc847ca9f233c8e141f473b
work_keys_str_mv	AT quarantal safetyandefficacyoftravoprostsolutionforthetreatmentofelevatedintraocularpressure AT rivai safetyandefficacyoftravoprostsolutionforthetreatmentofelevatedintraocularpressure AT katsanosa safetyandefficacyoftravoprostsolutionforthetreatmentofelevatedintraocularpressure AT florianii safetyandefficacyoftravoprostsolutionforthetreatmentofelevatedintraocularpressure AT centofantim safetyandefficacyoftravoprostsolutionforthetreatmentofelevatedintraocularpressure AT konstasag safetyandefficacyoftravoprostsolutionforthetreatmentofelevatedintraocularpressure
_version_	1718403924114800640

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure

Ejemplares similares